Clinical trials
for patients

The objective of this study is to evaluate the long-term tolerability and safety of the investigational drug TEV-56286 in people with AMS.

The objective of this trial, which involves research, is to examine the safety and efficacy of an investigational drug called LB-208. Investigational means that the investigational drug to be tested in this clinical trial has not been authorized by national drug regulatory agencies, such as the Spanish Agency of Medicines and Medical Devices.

The primary objective of this study is to determine whether STK-012 administered together with standard-of-care treatment is more effective in treating cancer than standard-of-care treatment alone in patients with lung cancer. STK-012 is a new investigational drug being studied by the sponsor.

Phase I study to determine the safety and tolerability of BI 3820768 in patients with advanced, relapsed, or treatment-refractory germ cell tumors, endometrial cancer, or ovarian cancer.

The primary objective is to compare the clinical efficacy of Rina-S with the investigator’s choice (IC) of treatment in patients with recurrent or progressive endometrial cancer (EC) following prior treatment.

The primary objective is to compare sac-TMT maintenance therapy with or without bevacizumab against standard of care (SoC) in terms of PFS as defined by RECIST 1.1, as assessed by the BICR.

You are invited to participate in this study because you have metastatic lung cancer. To participate in this study, your lung cancer must express a protein called programmed death-ligand 1 (PD-L1). PD-L1 is a protein found on cancer cells that can prevent the body’s immune system from attacking the cancer cells. Pembrolizumab is a treatment that blocks the effects of PD-L1 and allows the immune system to attack and kill cancer cells. Your disease must have a PD-L1 score of ≥50%. This re...

The purpose of this study is to learn more about the effectiveness and safety of the study drug, volrustomig (also known as MEDI5752), when given in combination with a standard treatment for colorectal cancer.

The goal is to continuously monitor your well-being and safety, and to ask you if you have started a new treatment. If, for any reason, the doctor or trial staff are unable to contact you, a family member may provide information about your condition, or the trial doctor may obtain it from sources such as your medical records, national or local registries, or publicly available information, as permitted by local regulations.

The trial consists of 3 parts. The objective of Part 1 is to assess the safety of GEN1079 at increasing doses and to identify the doses to be used in subsequent phases. The objective of Part 2 is to refine and identify the dose that is effective while causing the fewest side effects. The goal of Part 3 is to further investigate whether GEN1079 works against the tumor and how it does so, and to continue learning about its side effects.